Comparison of Mortality and Frequency of Red Blood Cell Allo-immunization in Recipients of Leukoreduced and Non-leukoreduced Whole Blood Transfusion in Uganda

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202302787440132

Enrollment

278

Registered

2023-02-06

Start date

2020-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Haematological Disorders

Interventions

Leucoreduced blood transfusion

Non leucoreduced blood

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: i. Patients admitted to adult ward in the Uganda Cancer Institute or Mulago hospital medical wards (aged 15 years and above) ii. Patients requiring blood transfusion iii. Patients who have provided a written informed consent/assent iv. Negative red blood cell allo-antibody test results at baseline

Exclusion criteria

Exclusion criteria: 1. Participation in a competing study 2. Blood transfusion required within 30 minutes preventing the performance of pre-enrollment study procedures. 3. Blood or platelets products transfused in the previous 48 hours before study enrollment 4. Absence of compatible blood units at the time of enrollment 5. Previously enrolled in the same study 6. Failure to obtain pre-transfusion blood sample for testing. 7. Patients with altered mental status or comatose

Design outcomes

Primary

Measure	Time frame
Mortality	—

Secondary

Measure	Time frame
Prevalence and incidence of RBC alloimmunization	—

Countries

Uganda

Contacts

Public ContactEzra Anecho

Grants Officer

ezraanecho@gmail.com+256750856488

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026